{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:50:29Z","timestamp":1788637829477,"version":"build-2803163510"},"reference-count":99,"publisher":"Jaypee Brothers Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.59556\/japi.73.1058","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:33:37Z","timestamp":1760081617000},"page":"e45-e60","source":"Crossref","is-referenced-by-count":6,"title":["MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians"],"prefix":"10.59556","volume":"73","author":[{"given":"Ashish","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(4):","key":"key20251010073330_B1","doi-asserted-by":"crossref","first-page":"1335\u2013","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.","volume":"77","author":"Younossi","year":"2023;","journal-title":"Hepatology"},{"issue":"(7):","key":"key20251010073330_B2","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(3):","key":"key20251010073330_B3","doi-asserted-by":"crossref","first-page":"818\u2013","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis.","volume":"12","author":"Shalimar,","year":"2022;","journal-title":"J Clin Exp Hepatol"},{"key":"key20251010073330_B4","doi-asserted-by":"crossref","first-page":"239\u2013","DOI":"10.1136\/flgastro-2024-102856","article-title":"Role of anti-diabetic medications in the management of MASLD.","volume":"16:","author":"Isaacs","year":"2025;","journal-title":"Frontline Gastroenterol"},{"issue":"(6):","key":"key20251010073330_B5","doi-asserted-by":"crossref","first-page":"1542\u2013","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023;","journal-title":"J Hepatol"},{"issue":"(10290):","key":"key20251010073330_B6","doi-asserted-by":"crossref","first-page":"2212\u2013","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021;","journal-title":"Lancet"},{"issue":"(18):","key":"key20251010073330_B7","doi-asserted-by":"crossref","first-page":"1675\u2013","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.","volume":"362","author":"Sanyal","year":"2010;","journal-title":"N Engl J Med"},{"issue":"(10):","key":"key20251010073330_B8","first-page":"e72596.","article-title":"Vitamin E and non-alcoholic fatty liver disease: investigating the evidence through a systematic review.","volume":"16","author":"Abera","year":"2024;","journal-title":"Cureus"},{"issue":"(2):","key":"key20251010073330_B9","doi-asserted-by":"crossref","first-page":"101939.","DOI":"10.1016\/j.xcrm.2025.101939","article-title":"Vitamin E (300 mg) in the treatment of MASH: a multi-center, randomized, double-blind, placebo-controlled study.","volume":"6","author":"Song","year":"2025;","journal-title":"Cell Rep Med"},{"issue":"(14):","key":"key20251010073330_B10","doi-asserted-by":"crossref","first-page":"1549\u2013","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT).","volume":"306","author":"Klein","year":"2011;","journal-title":"JAMA"},{"issue":"(9):","key":"key20251010073330_B11","doi-asserted-by":"crossref","first-page":"2153.","DOI":"10.3390\/nu11092153","article-title":"Circulating vitamin E levels and risk of coronary artery disease and myocardial infarction: a mendelian randomization study.","volume":"11","author":"Wang","year":"2019;","journal-title":"Nutrients"},{"issue":"(1):","key":"key20251010073330_B12","doi-asserted-by":"crossref","first-page":"51\u2013","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.","volume":"59","author":"Harrison","year":"2024;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(11):","key":"key20251010073330_B13","doi-asserted-by":"crossref","first-page":"2919\u2013","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.","volume":"29","author":"Harrison","year":"2023;","journal-title":"Nat Med"},{"issue":"(6):","key":"key20251010073330_B14","doi-asserted-by":"crossref","first-page":"497\u2013","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.","volume":"390","author":"Harrison","year":"2024;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20251010073330_B15","doi-asserted-by":"crossref","first-page":"312\u2013","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.","volume":"81","author":"Chen","year":"2025;","journal-title":"Hepatology"},{"issue":"(3):","key":"key20251010073330_B16","first-page":"492\u2013","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO).","year":"2024;","journal-title":"J Hepatol"},{"issue":"(12):","key":"key20251010073330_B17","doi-asserted-by":"crossref","first-page":"1113\u2013","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021;","journal-title":"N Engl J Med"},{"issue":"(21):","key":"key20251010073330_B18","doi-asserted-by":"crossref","first-page":"2089\u2013","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.","volume":"392","author":"Sanyal","year":"2025;","journal-title":"N Engl J Med"},{"issue":"(6):","key":"key20251010073330_B19","doi-asserted-by":"crossref","first-page":"653\u2013","DOI":"10.4103\/ijem.ijem_266_24","article-title":"Effectiveness of oral semaglutide in management of type 2 diabetes: a real-world study from India.","volume":"28","author":"Dutta","year":"2024;","journal-title":"Indian J Endocrinol Metab"},{"issue":"(11):","key":"key20251010073330_B20","doi-asserted-by":"crossref","first-page":"4958\u2013","DOI":"10.1111\/dom.15898","article-title":"Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study.","volume":"26","author":"Arai","year":"2024;","journal-title":"Diabetes Obes Metab"},{"issue":"(1):","key":"key20251010073330_B21","doi-asserted-by":"crossref","first-page":"129.","DOI":"10.3390\/ph18010129","article-title":"The effects of oral semaglutide on hepatic fibrosis in subjects with type 2 diabetes in real-world clinical practice: a post hoc analysis of the Sapporo-Oral SEMA study.","volume":"18","author":"Kitsunai","year":"2025;","journal-title":"Pharmaceuticals"},{"issue":"(6):","key":"key20251010073330_B22","doi-asserted-by":"crossref","first-page":"603\u2013","DOI":"10.1507\/endocrj.EJ23-0648","article-title":"Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).","volume":"71","author":"Furusawa","year":"2024;","journal-title":"Endocr J"},{"issue":"(14):","key":"key20251010073330_B23","doi-asserted-by":"crossref","first-page":"1475.","DOI":"10.3390\/diagnostics14141475","article-title":"New insights on using oral semaglutide versus dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.","volume":"14","author":"Stratina","year":"2024;","journal-title":"Diagnostics"},{"issue":"(8):","key":"key20251010073330_B24","doi-asserted-by":"crossref","first-page":"186.","DOI":"10.3390\/diseases12080186","article-title":"Therapeutic effects of semaglutide on nonalcoholic fatty liver disease with type 2 diabetes mellitus and obesity: an open-label controlled trial.","volume":"12","author":"Gad","year":"2024;","journal-title":"Diseases"},{"issue":"(10019):","key":"key20251010073330_B25","doi-asserted-by":"crossref","first-page":"679\u2013","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016;","journal-title":"Lancet"},{"issue":"(11):","key":"key20251010073330_B26","doi-asserted-by":"crossref","first-page":"2434\u2013","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).","volume":"63","author":"Kuchay","year":"2020;","journal-title":"Diabetologia"},{"issue":"(1):","key":"key20251010073330_B27","doi-asserted-by":"crossref","first-page":"12\u2013","DOI":"10.3803\/EnM.2024.1942","article-title":"The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor\u2014an update.","volume":"39","author":"Jakubowska","year":"2024;","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"(4):","key":"key20251010073330_B28","doi-asserted-by":"crossref","first-page":"299\u2013","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.","volume":"391","author":"Loomba","year":"2024;","journal-title":"N Engl J Med"},{"issue":"(4):","key":"key20251010073330_B29","doi-asserted-by":"crossref","first-page":"311\u2013","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis.","volume":"391","author":"Sanyal","year":"2024;","journal-title":"N Engl J Med"},{"issue":"(7):","key":"key20251010073330_B30","doi-asserted-by":"crossref","first-page":"2037\u2013","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.","volume":"30","author":"Sanyal","year":"2024;","journal-title":"Nat Med"},{"key":"key20251010073330_B31","doi-asserted-by":"crossref","first-page":"615409.","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis.","volume":"12:","author":"Lian","year":"2021;","journal-title":"Front Endocrinol"},{"issue":"(46):","key":"key20251010073330_B32","doi-asserted-by":"crossref","first-page":"e31508.","DOI":"10.1097\/MD.0000000000031508","article-title":"Pioglitazone on nonalcoholic steatohepatitis: a systematic review and meta-analysis of 15 RCTs.","volume":"101","author":"Zhao","year":"2022;","journal-title":"Medicine (Baltimore)"},{"issue":"(4):","key":"key20251010073330_B33","doi-asserted-by":"crossref","first-page":"980\u2013","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis.","volume":"23","author":"Panunzi","year":"2021;","journal-title":"Diabetes Obes Metab"},{"issue":"(3):","key":"key20251010073330_B34","doi-asserted-by":"crossref","first-page":"273\u2013","DOI":"10.1080\/17474124.2023.2172397","article-title":"Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.","volume":"17","author":"Gu","year":"2023;","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"key20251010073330_B35","doi-asserted-by":"crossref","first-page":"1111430.","DOI":"10.3389\/fendo.2023.1111430","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: a meta-analysis of randomized controlled trials.","volume":"14:","author":"Wang","year":"2023;","journal-title":"Front Endocrinol"},{"issue":"(1):","key":"key20251010073330_B36","doi-asserted-by":"crossref","first-page":"66\u2013","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.","volume":"35","author":"Boettcher","year":"2012;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(4):","key":"key20251010073330_B37","doi-asserted-by":"crossref","first-page":"1809\u2013","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial.","volume":"74","author":"Gawrieh","year":"2021;","journal-title":"Hepatology"},{"key":"key20251010073330_B38","doi-asserted-by":"crossref","first-page":"435\u2013","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients.","volume":"12:","author":"Padole","year":"2022;","journal-title":"J Clin Exp Hepatol"},{"issue":"(10):","key":"key20251010073330_B39","doi-asserted-by":"crossref","first-page":"2597\u2013","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis.","volume":"21","author":"Siddiqui","year":"2023;","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"(7):","key":"key20251010073330_B40","doi-asserted-by":"crossref","first-page":"102174.","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis.","volume":"47","author":"Bandyopadhyay","year":"2023;","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"(5):","key":"key20251010073330_B41","doi-asserted-by":"crossref","first-page":"101398.","DOI":"10.1016\/j.jceh.2024.101398","article-title":"A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-SVIN TRIAL.","volume":"14","author":"Mir","year":"2024;","journal-title":"J Clin Exp Hepatol"},{"issue":"(3):","key":"key20251010073330_B42","doi-asserted-by":"crossref","first-page":"215\u2013","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience.","volume":"7","author":"Chaudhuri","year":"2023;","journal-title":"JGH Open"},{"issue":"(10):","key":"key20251010073330_B43","first-page":"e47493.","article-title":"Saroglitazar in non-alcoholic fatty liver disease from bench to bedside: a comprehensive review and sub-group meta-analysis.","volume":"15","author":"Roy","year":"2023;","journal-title":"Cureus"},{"issue":"(17):","key":"key20251010073330_B44","doi-asserted-by":"crossref","first-page":"1547\u2013","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH.","volume":"385","author":"Francque","year":"2021;","journal-title":"N Engl J Med"},{"key":"key20251010073330_B45","doi-asserted-by":"crossref","first-page":"979\u2013","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.","volume":"82:","author":"Barb","year":"2025;","journal-title":"J Hepatol"},{"key":"key20251010073330_B46","doi-asserted-by":"crossref","first-page":"106170.","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study.","volume":"98:","author":"Sven M","year":"2020;","journal-title":"Contemp Clin Trials"},{"key":"key20251010073330_B47","article-title":"FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes.","author":"FDA."},{"issue":"(1):","key":"key20251010073330_B48","first-page":"21\u2013","article-title":"Canagliflozin and amputation risk: evidence so far.","volume":"19","author":"Papadokostaki","year":"2019;","journal-title":"Int J Low Extrem Wounds"},{"issue":"(Suppl 5):","key":"key20251010073330_B49","doi-asserted-by":"crossref","first-page":"5\u2013","DOI":"10.1111\/dom.15751","article-title":"An overview of the CANVAS program and CREDENCE trial: the primary outcomes and key clinical implications for those managing patients with type 2 diabetes.","volume":"26","author":"Chen","year":"2024;","journal-title":"Diabetes Obes Metab"},{"issue":"(2):","key":"key20251010073330_B50","doi-asserted-by":"crossref","first-page":"284\u2013","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.","volume":"74","author":"Bea","year":"2025;","journal-title":"Gut"},{"issue":"(12):","key":"key20251010073330_B51","doi-asserted-by":"crossref","first-page":"1120\u2013","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.","volume":"59","author":"Kawaguchi","year":"2024;","journal-title":"J Gastroenterol"},{"issue":"(4):","key":"key20251010073330_B52","doi-asserted-by":"crossref","first-page":"101876.","DOI":"10.1016\/j.clinre.2022.101876","article-title":"Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","volume":"46","author":"Sun","year":"2022;","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"key20251010073330_B53","doi-asserted-by":"crossref","first-page":"836455.","DOI":"10.3389\/fendo.2022.836455","article-title":"Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"13:","author":"Zhang","year":"2022;","journal-title":"Front Endocrinol"},{"issue":"(1):","key":"key20251010073330_B54","doi-asserted-by":"crossref","first-page":"2122.","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.","volume":"14","author":"Lopez","year":"2024;","journal-title":"Sci Rep"},{"key":"key20251010073330_B55","doi-asserted-by":"crossref","first-page":"e083735.","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.","volume":"389:","author":"Lin","year":"2025;","journal-title":"BMJ"},{"issue":"(3):","key":"key20251010073330_B56","article-title":"Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes.","volume":"19","author":"Misra","year":"2025;","journal-title":"Diabetes Metab Syndr"},{"issue":"(4):","key":"key20251010073330_B57","doi-asserted-by":"crossref","first-page":"916\u2013","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial.","volume":"80","author":"Cheung","year":"2024;","journal-title":"Hepatology"},{"issue":"(2):","key":"key20251010073330_B58","doi-asserted-by":"crossref","first-page":"173\u2013","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.","volume":"68","author":"Tobita","year":"2021;","journal-title":"J Clin Biochem Nutr"},{"issue":"(3):","key":"key20251010073330_B59","first-page":"433\u2013","article-title":"Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes.","volume":"4","author":"Marjot","year":"2019;","journal-title":"JGH Open"},{"issue":"(3):","key":"key20251010073330_B60","doi-asserted-by":"crossref","first-page":"e70023.","DOI":"10.1111\/liv.70023","article-title":"Gut microbiota predicts treatment response to empagliflozin among MASLD patients without diabetes mellitus.","volume":"45","author":"Ng","year":"2025;","journal-title":"Liver Int"},{"key":"key20251010073330_B61","doi-asserted-by":"crossref","first-page":"601349.","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human.","volume":"11:","author":"Henriksson","year":"2020;","journal-title":"Front Endocrinol"},{"issue":"(12):","key":"key20251010073330_B62","doi-asserted-by":"crossref","first-page":"1080\u2013","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.","volume":"8","author":"Harrison","year":"2023;","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"(11):","key":"key20251010073330_B63","doi-asserted-by":"crossref","first-page":"998\u2013","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH.","volume":"389","author":"Loomba","year":"2023;","journal-title":"N Engl J Med"},{"issue":"(10215):","key":"key20251010073330_B64","doi-asserted-by":"crossref","first-page":"2184\u2013","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"394","author":"Younossi","year":"2019;","journal-title":"Lancet"},{"issue":"(5):","key":"key20251010073330_B65","doi-asserted-by":"crossref","first-page":"1110\u2013","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.","volume":"79","author":"Sanyal","year":"2023;","journal-title":"J Hepatol"},{"issue":"(1):","key":"key20251010073330_B66","doi-asserted-by":"crossref","first-page":"58\u2013","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial.","volume":"72","author":"Patel","year":"2020;","journal-title":"Hepatology"},{"issue":"(12):","key":"key20251010073330_B67","doi-asserted-by":"crossref","first-page":"1090\u2013","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.","volume":"9","author":"Loomba","year":"2024;","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"(7):","key":"key20251010073330_B68","doi-asserted-by":"crossref","first-page":"603\u2013","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial.","volume":"7","author":"Harrison","year":"2022;","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"(4):","key":"key20251010073330_B69","doi-asserted-by":"crossref","first-page":"944\u2013","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"56","author":"Parker","year":"2012;","journal-title":"J Hepatol"},{"issue":"(9):","key":"key20251010073330_B70","doi-asserted-by":"crossref","first-page":"2769.","DOI":"10.3390\/nu12092769","article-title":"Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: a systematic review and meta-analysis.","volume":"12","author":"Lee","year":"2020;","journal-title":"Nutrients"},{"issue":"(2):","key":"key20251010073330_B71","doi-asserted-by":"crossref","first-page":"143\u2013","DOI":"10.1093\/nutrit\/nuad054","article-title":"A systematic review and meta-analysis of randomized controlled trials to evaluate plant-based omega-3 polyunsaturated fatty acids in nonalcoholic fatty liver disease patient biomarkers and parameters.","volume":"82","author":"Moore","year":"2024;","journal-title":"Nutr Rev"},{"issue":"(3):","key":"key20251010073330_B72","doi-asserted-by":"crossref","first-page":"770\u2013","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.","volume":"39","author":"Lindor","year":"2004;","journal-title":"Hepatology"},{"issue":"(2):","key":"key20251010073330_B73","doi-asserted-by":"crossref","first-page":"472\u2013","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.","volume":"52","author":"Leuschner","year":"2010;","journal-title":"Hepatology"},{"key":"key20251010073330_B74","doi-asserted-by":"crossref","first-page":"140.","DOI":"10.1186\/1471-230X-13-140","article-title":"The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.","volume":"13:","author":"Xiang","year":"2013;","journal-title":"BMC Gastroenterol"},{"issue":"(5):","key":"key20251010073330_B75","first-page":"294\u2013","article-title":"Ursodeoxycholic acid: efficacy and safety in the treatment of nonalcoholic fatty liver disease (meta-analysis).","volume":"73","author":"Pavlov","year":"2018;","journal-title":"Ann Russ Acad Med Sci"},{"issue":"(6):","key":"key20251010073330_B76","doi-asserted-by":"crossref","first-page":"537\u2013","DOI":"10.1080\/17474124.2022.2083605","article-title":"Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis.","volume":"16","author":"Lin","year":"2022;","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"(1):","key":"key20251010073330_B77","doi-asserted-by":"crossref","first-page":"92\u2013","DOI":"10.5005\/jp-journals-10018-1434","article-title":"Ursodeoxycholic acid\u2019s effectiveness in the management of nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"14","author":"Patel","year":"2024;","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"key20251010073330_B78","doi-asserted-by":"crossref","first-page":"S181\u2013","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025.","volume":"48:","author":"American Diabetes Association Professional Practice Committee.","year":"2025;","journal-title":"Diabetes Care"},{"issue":"(16):","key":"key20251010073330_B79","doi-asserted-by":"crossref","first-page":"1659\u2013","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.","volume":"305","author":"Lavine","year":"2011;","journal-title":"JAMA"},{"issue":"(1):","key":"key20251010073330_B80","doi-asserted-by":"crossref","first-page":"57\u2013","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"1","author":"Li","year":"2013;","journal-title":"Biomed Rep"},{"issue":"(7):","key":"key20251010073330_B81","doi-asserted-by":"crossref","first-page":"2347\u2013","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"97","author":"Zhang","year":"2012;","journal-title":"J Clin Endocrinol Metab"},{"issue":"(9):","key":"key20251010073330_B82","first-page":"823\u2013","article-title":"Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.","volume":"29","author":"Murff","year":"2018;","journal-title":"Cancer Causes Control"},{"key":"key20251010073330_B83","doi-asserted-by":"crossref","first-page":"100768.","DOI":"10.1016\/j.curtheres.2024.100768","article-title":"Impact of dipeptidyl peptidase-4 inhibitors on aminotransferases levels in patients with type 2 diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trial.","volume":"102:","author":"Ma","year":"2024;","journal-title":"Curr Ther Res Clin Exp"},{"issue":"(3):","key":"key20251010073330_B84","doi-asserted-by":"crossref","first-page":"235\u2013","DOI":"10.1016\/j.dld.2016.12.028","article-title":"Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?","volume":"49","author":"Mazzotti","year":"2017;","journal-title":"Dig Liver Dis"},{"issue":"(3):","key":"key20251010073330_B85","doi-asserted-by":"crossref","first-page":"206\u2013","DOI":"10.2337\/diab.32.3.206","article-title":"Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats.","volume":"32","author":"Salhanick","year":"1983;","journal-title":"Diabetes"},{"issue":"(7):","key":"key20251010073330_B86","doi-asserted-by":"crossref","first-page":"1339\u2013","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial.","volume":"38","author":"Tang","year":"2015;","journal-title":"Diabetes Care"},{"key":"key20251010073330_B87","doi-asserted-by":"crossref","first-page":"100254.","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies.","volume":"20:","author":"Hayat","year":"2021;","journal-title":"Ann Hepatol"},{"issue":"(5):","key":"key20251010073330_B88","doi-asserted-by":"crossref","first-page":"1740\u2013","DOI":"10.1053\/j.gastro.2007.03.044","article-title":"Coffee consumption and risk of liver cancer: a meta-analysis.","volume":"132","author":"Larsson","year":"2007;","journal-title":"Gastroenterology"},{"issue":"(10):","key":"key20251010073330_B89","doi-asserted-by":"crossref","first-page":"2983.","DOI":"10.3390\/nu12102983","article-title":"Dietary strategies for metabolic syndrome: a comprehensive review.","volume":"12","author":"Castro-Barquero","year":"2020;","journal-title":"Nutrients"},{"issue":"(12):","key":"key20251010073330_B90","doi-asserted-by":"crossref","first-page":"4406.","DOI":"10.3390\/nu13124406","article-title":"The relationship between macronutrient distribution and type 2 diabetes in Asian Indians.","volume":"13","author":"Pandya","year":"2021;","journal-title":"Nutrients"},{"issue":"(2):","key":"key20251010073330_B91","doi-asserted-by":"crossref","first-page":"273\u2013","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian National Association for Study of the Liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD).","volume":"13","author":"Duseja","year":"2023;","journal-title":"J Clin Exp Hepatol"},{"key":"key20251010073330_B92","doi-asserted-by":"crossref","first-page":"156028.","DOI":"10.1016\/j.metabol.2024.156028","article-title":"The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus.","volume":"161:","author":"Zeng","year":"2024;","journal-title":"Metabolism"},{"issue":"(14):","key":"key20251010073330_B93","doi-asserted-by":"crossref","first-page":"1992.","DOI":"10.3390\/healthcare11141992","article-title":"Physical activity protocols in non-alcoholic fatty liver disease management: a systematic review of randomized clinical trials and animal models.","volume":"11","author":"Barr\u00f3n-Cabrera","year":"2023;","journal-title":"Healthcare"},{"issue":"(1):","key":"key20251010073330_B94","doi-asserted-by":"crossref","first-page":"e16220.","DOI":"10.1111\/liv.16220","article-title":"The role of exercise in steatotic liver diseases: an updated perspective.","volume":"45","author":"Razzak","year":"2025;","journal-title":"Liver Int"},{"issue":"(2):","key":"key20251010073330_B95","doi-asserted-by":"crossref","first-page":"44.","DOI":"10.3390\/jfmk8020044","article-title":"Insights into non-exercise physical activity on control of body mass: a review with practical recommendations.","volume":"8","author":"Bonilla","year":"2023;","journal-title":"J Funct Morphol Kinesiol"},{"issue":"(3):","key":"key20251010073330_B96","doi-asserted-by":"crossref","first-page":"e219\u2013","DOI":"10.1016\/S2468-2667(21)00302-9","article-title":"Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts.","volume":"7","author":"Paluch","year":"2022;","journal-title":"Lancet Public Health"},{"issue":"(2):","key":"key20251010073330_B97","doi-asserted-by":"crossref","first-page":"367\u2013","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.","volume":"149","author":"Vilar-Gomez","year":"2015;","journal-title":"Gastroenterology"},{"issue":"(5):","key":"key20251010073330_B98","doi-asserted-by":"crossref","first-page":"305\u2013","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.","volume":"165","author":"Cusi","year":"2016;","journal-title":"Ann Intern Med"},{"key":"key20251010073330_B99","doi-asserted-by":"crossref","first-page":"305\u2013","DOI":"10.1016\/j.clnesp.2023.07.013","article-title":"Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: a retrospective study.","volume":"57:","author":"Tyagi","year":"2023;","journal-title":"Clin Nutr ESPEN"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:33:47Z","timestamp":1760081627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-73-7-e45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.59556\/japi.73.1058"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.1058","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}